Votre événement devrait être ici ! Pour référencer, gérer, promouvoir... Pour s'informer ou se former ... Inscriptions en ligne

Langue du site : Français - English
Réf : 30778
Evènement :SMi's 22nd Annual Superbugs and Superdrugs Conference

Dates :Lundi 30 Mars 2020 - Mardi 31 Mars 2020

London, Royaume-Uni

Type :Conférence & Séminaire - Audience Internationale

Accréditation :--




Sponsored by Scynexis

Cara Cassino, Chief Medical Officer, Contrafect
Michael Dawson, Director, Mike Dawson Antimicrobial Research Consultancy

As one of the most impactful pharmaceuticals for maintaining public health, antibiotics have been around since early 20th century and have since shown a need for significant progress in recent years. This is mainly due to its broad and indiscriminate use which has slowly given birth to multi- to extensively-drug resistant bacteria rendering our current last-resort antibiotic arsenal, including colistin, carbapenems, 3rd and 4th generation cephalosporins, useless.
This year’s event aims to showcase a suite of sessions focused on novel drugs and approaches, particularly highlighting non-traditional and traditional therapies that provide an innovative means to spearhead the issue. The conference will also place significant emphasis on the much-needed support for innovative approaches such as sessions tackling the funding and support and the regulation that provides guidance towards the goal of ameliorating the continued rise of anti-microbial resistance AMR.
It is crucial to bring industry leaders together to discuss the strategies in place that reduce AMR, evaluate the role pharmaceutical companies and funding bodies play in reducing AMR, learn about new diagnostics approaches to identify AMR and consider novel candidates and alternatives to anti-microbials. Join us in March 2020, along with leaders from the pharmaceutical industry, academia, regulatory and funding bodies, and public-private partnerships to discuss the way forward.




Website: https://go.evvnt.com/538855-0?pid=4319

Tickets: https://go.evvnt.com/538855-2?pid=4319

Brochure: https://go.evvnt.com/538855-3?pid=4319

Sponsor: https://go.evvnt.com/538855-4?pid=4319

Speakers: CO-CHAIR - Cara Cassino, Chief Medical Officer, Contrafect, CO-CHAIR - Michael Dawson, Director, Mike Dawson Antimicrobial Research Consultancy, Yuri Gleba, Professor, Founder, Nomad Bioscience, Samareh Lajaunias, Director, Combioxin SA, Cara Cassino, Chief Medical Officer, Contrafec, Mark Albrecht, Branch Chief, Antibacterials Program, BARDA/HHS, Stephen Barat, VP, Research and Early Development, Scynexis, Pedro Madureira, Co-Founder, CSO, Immunethep, Pedro Madureira, Co-Founder, CSO, Immunethep, Toni Perez, Chief Medical Officer, Senior Subject Matter Expert, Combioxin, Colm Leonard, Consultant Clinical Adviser/Consultant Thoracic Physician/Honorary Professor of Medicine, NICE and Machester University NHS Foundation Trust, Paul Finn, CEO, Oxford Drug Design, Martin Everett, CSO, Antabio, Francois Moreau, Scientific Director, Mutabilis, Daniel Walker, Professor of Bacteriology, University of Glasgow, Lorenzo Corsini, Co-Founder/CEO/R&D, Phagomed, David Roper, Professor of Biochemistry and Structural Biology, University of Warwick, Emma Leire, Microbiology Lead, Centauri Therapeutics, Peter Warn, Senior Vice President Anti-infective Discovery, Evotec (UK) Ltd, Antonio Felici, VP, Anti-Infectives, Evotec, Stephen Barat, VP, Preclinical Research and Early Development, Scynexis

Time: 8:30 am - 4:40 pm


Plan et itinéraire
Adresse de la conférence :
Plan et itinéraire


Pour accéder aux informations vous devez être connecté. Créer un compte est facile et gratuit!

Connexion à votre compte
S'inscrire sur Doctorama


SMi's 22nd Annual Superbugs and Superdrugs Conference Médecine - Pharmacie
100 -- --


Pour plus d'informations sur SMi's 22nd Annual Superbugs and Superdrugs Conference, veuillez contacter SMi Group

Pour obtenir une lettre d'invitation, vous devez être connecté

Connexion à votre compte
S'inscrire sur Doctorama

Recommander cet évènement